ImageneBio, Inc. Reports Leadership Changes and Compensation Updates
Ticker: IMA · Form: 8-K · Filed: Oct 10, 2025 · CIK: 1835579
| Field | Detail |
|---|---|
| Company | Imagenebio, INC. (IMA) |
| Form Type | 8-K |
| Filed Date | Oct 10, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-compensation, corporate-governance
TL;DR
ImageneBio (formerly Ikena Oncology) just filed an 8-K: new execs elected, old ones out, comp plans updated. Watch this space.
AI Summary
On October 10, 2025, ImageneBio, Inc. filed an 8-K report detailing changes in its leadership and executive compensation. The filing indicates the departure of certain directors or officers, the election of new directors, and the appointment of certain officers, along with updates to compensatory arrangements for these key individuals. The company, formerly known as Ikena Oncology, Inc., is based in San Diego, California.
Why It Matters
Changes in a company's board of directors and executive officers, along with their compensation, can signal shifts in strategy or operational focus, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Leadership changes and executive compensation adjustments can introduce uncertainty about the company's future direction and stability.
Key Numbers
- 001-40287 — SEC File Number (Identifies the company's filing history with the SEC.)
- 811697316 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- ImageneBio, Inc. (company) — Registrant
- Ikena Oncology, Inc. (company) — Former company name
- October 10, 2025 (date) — Date of report
- San Diego, California (location) — Principal executive offices
- Delaware (location) — State of incorporation
FAQ
Who specifically departed from ImageneBio, Inc.'s board or officer positions?
The filing indicates the departure of 'Directors or Certain Officers' but does not name the specific individuals in this section of the provided text.
Who were elected as new directors or appointed as officers?
The filing mentions the 'Election of Directors' and 'Appointment of Certain Officers' but does not provide the names of these individuals in the provided text.
What are the specific changes to the compensatory arrangements for the officers?
The filing notes 'Compensatory Arrangements of Certain Officers' have been updated, but the details of these arrangements are not specified in the provided text.
When did ImageneBio, Inc. change its name from Ikena Oncology, Inc.?
The filing states the former company name was Ikena Oncology, Inc. and the date of name change was December 8, 2020.
What is ImageneBio, Inc.'s primary business sector?
ImageneBio, Inc. is in the 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' sector, with SIC code [2836].
Filing Stats: 412 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2025-10-10 16:45:56
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value IMA The Nasdaq Capital Ma
Filing Documents
- d25863d8k.htm (8-K) — 23KB
- 0001193125-25-237161.txt ( ) — 137KB
- ima-20251010.xsd (EX-101.SCH) — 3KB
- ima-20251010_lab.xml (EX-101.LAB) — 18KB
- ima-20251010_pre.xml (EX-101.PRE) — 11KB
- d25863d8k_htm.xml (XML) — 4KB
From the Filing
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2025 IMAGENEBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 12526 High Bluff Drive , Suite 345 San Diego , California 92130 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (858) 345-6265 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value IMA The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 10, 2025, Jotin Marango, M.D., Ph.D., our Chief Financial Officer and principal financial officer, provided notice of his resignation, effective October 20, 2025. Dr. Marango's resignation was not due to any disagreement with the Company. We plan to conduct a search for Dr. Marango's replacement. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMAGENEBIO, INC. Date: October 10, 2025 By: /s/ Kristin Yarema Kristin Yarema, Ph.D. Chief Executive Officer